Getein Biotech, Inc (603387) Fair Value & Analysis

Healthcare · CN · Market cap 4.1B CNY

Analysis

Getein Biotech, Inc (603387) currently trades at ¥7.95, while our model-based Fair Value estimate is ¥9.12 — implying the stock looks roughly 14.7% undervalued today. We read business quality at 91/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Getein Biotech, Inc researches, develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. The company provides point-of-care detection, chemiluminescence detection, biochemical analysis, molecular testing, thrombus and hemostasis detection, blood cell analysis detection, urine analysis, quality control products, diagnostic raw materials, biochemical immunity, and other fields, such as myocardium, inflammation, renal function, thyroid function, hormones, glucose metabolism, tumor, coagulation, blood cells detection. The company was founded in 2002 and is headquartered in Nanjing, China.

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.